Managing Agitation and Psychosis in Dementia

A Hierarchical, Evidence-Based Clinical Guide for Psychiatric Nurse Practitioners

Executive Summary

Key Points:

  • BPSD affects 90%+ of dementia patients during their disease course
  • Always rule out medical causes before attributing to dementia (UTI, pain, delirium)
  • DICE framework: Describe → Investigate → Create → Evaluate
  • Antipsychotics carry black box warning: 1.6-1.7x increased mortality risk
  • Plan to de-prescribe: Evidence supports efficacy for only 6-12 weeks

Behavioral and Psychological Symptoms of Dementia (BPSD) represent one of the most challenging aspects of dementia care. This evidence-based guide provides a structured, hierarchical approach that prioritizes safety, non-pharmacological interventions, and judicious medication use when necessary.

Section 1: The Foundational Assessment

Before Any Intervention: Differential Diagnosis

Before attributing behaviors to BPSD, systematically rule out underlying causes:

🔍 Medical Causes Checklist

  • Infections: UTI, pneumonia, skin infections
  • Pain: Unrecognized pain from arthritis, fractures, dental issues, constipation
  • Metabolic: Dehydration, electrolyte imbalances, hypoglycemia
  • Medication review: Anticholinergics, benzodiazepines, new medications
  • Delirium screening: Acute confusional states often mistaken for BPSD

Environmental Triggers Assessment

Trigger CategoryExamplesIntervention
OverstimulationExcessive noise, bright lights, crowded spacesQuiet environment, reduce stimuli
UnderstimulationBoredom, lack of meaningful activitiesStructured activities, music therapy
Routine disruptionsChanges in caregivers, meal timesConsistent schedule, familiar faces
Physical environmentPoor lighting, temperature extremesOptimize lighting, comfortable temperature

Behavioral Characterization: The DICE Approach

ComponentAssessment Questions
FrequencyHow often does it occur? Daily, weekly, sporadic?
IntensityMild, moderate, or severe (safety risk)?
DurationHow long do episodes last?
TriggersTime of day, specific activities, particular caregivers?
ContextWhere does it occur? What precedes/follows?
ImpactEffect on patient safety, caregiver burden, quality of life

Section 2: Non-Pharmacological Management (First-Line)

1. Describe
Document behavior
→
2. Investigate
Medical, caregiver, environment
→
3. Create
Individualized plan
→
4. Evaluate
Assess outcomes

Communication Strategies

Validation Therapy:

  • Acknowledge emotions: "I can see you're worried"
  • Enter their reality: "Tell me about your mother" (don't correct)
  • Match emotional tone while remaining calm

De-escalation: The BANGS Framework

LetterActionImplementation
BBreatheTake slow, deep breaths; model calmness
AAgreeValidate feelings even if not the facts
NNever argueDon't confront delusions or try to convince
GGo with the flowRedirect rather than oppose
SSay sorryAcknowledge their distress

Section 3: Pharmacological Management (Second-Line)

⚠️ FDA Black Box Warning

Antipsychotics are associated with increased risk of mortality in elderly patients with dementia-related psychosis (1.6-1.7x risk). Primary causes: cardiovascular events and infections (particularly pneumonia).

Stroke Risk: 2-fold increased risk of cerebrovascular events.

Antipsychotic Selection Hierarchy

DrugEvidenceStarting DoseTarget DoseKey Monitoring
RisperidoneStrongest0.25-0.5 mg0.5-1.5 mgEPS, hypotension, prolactin
OlanzapineModerate2.5-5 mg5-10 mgWeight, diabetes, lipids
AripiprazoleModerate2.5-5 mg7.5-12.5 mgAkathisia, insomnia
QuetiapineLimited12.5-25 mg50-200 mgSedation, hypotension

Avoid in BPSD:

  • Benzodiazepines: Increased falls, cognitive impairment, paradoxical agitation
  • Valproate: NICE guidelines specifically recommend against
  • Anticholinergics: Worsen cognition and confusion

Alternative: SSRIs for Agitation

MedicationDosingKey Considerations
CitalopramMax 20mg/day (>60y)QT prolongation risk
Sertraline25mg → 50-100mgSafer cardiac profile

Section 4: Monitoring and De-prescribing

Monitoring Protocol

TimeframeAssessment
Week 2Acute side effects, sedation, falls
MonthlyWeight, BP, EPS assessment
Every 3-6 monthsMetabolic panel, lipids, HbA1c (olanzapine)
Every 3-6 monthsAIMS Scale (tardive dyskinesia screening)

🎯 Reassess at 4 Weeks

Discontinue if no benefit observed. Evidence supports antipsychotic efficacy for only 6-12 weeks in BPSD.

De-prescribing Algorithm

Stable 3-6 months
No safety incidents
→
Reduce dose
25-50% every 1-2 weeks
→
Monitor weekly
During taper
→
If relapse:
Resume previous dose

Sample Risperidone Taper

PhaseDoseDuration
11mg → 0.75mg dailyWeeks 1-2
20.75mg → 0.5mg dailyWeeks 3-4
30.5mg → 0.25mg dailyWeeks 5-6
40.25mg → 0.125mg dailyWeeks 7-8
5DiscontinueWeeks 9-10

Quick Reference

Informed Consent Script

"I'm recommending an antipsychotic medication for [patient's name]'s severe agitation that hasn't responded to other approaches. These medications carry serious warnings. Studies show a small but real increased risk of stroke and death—about 1-2 additional cases per 100 people treated. However, severe untreated agitation also poses risks. We'll use the lowest dose for the shortest time possible, with regular monitoring. What questions do you have about these risks and benefits?"

Red Flags Requiring Immediate Medical Evaluation